Jazz Pharmaceuticals IPO Will Fund Luvox CR Commercialization
Executive Summary
Jazz Pharmaceuticals is hoping to raise more than $100 million through its initial public offering to help fund the commercialization of its lead compound, Luvox CR (see chart: "1Jazz Pharmaceuticals IPO")
You may also be interested in...
It's Fusion As Jazz Pharmaceuticals, Azur Pharma Reach Merger Agreement
The maker of narcolepsy drug Xyrem gets a portfolio of CNS and women's health drugs while moving its headquarters to Ireland, saving millions on taxes.
Sales Rep “Ride Alongs” Required As Part Of Jazz’s Xyrem Settlement
Jazz Pharmaceuticals' sales reps will have limited opportunities for improvisation under a corporate integrity agreement signed to settle charges of off-label detailing of Xyrem (gamma-hydroxybutyrate)
Sales Rep “Ride Alongs” Required As Part Of Jazz’s Xyrem Settlement
Jazz Pharmaceuticals' sales reps will have limited opportunities for improvisation under a corporate integrity agreement signed to settle charges of off-label detailing of Xyrem (gamma-hydroxybutyrate)